IDEAYA and Pfizer Expand CTC and Supply Agreement for Solid Tumors Harboring GNAQ or GNA11 Mutations

 IDEAYA and Pfizer Expand CTC and Supply Agreement for Solid Tumors Harboring GNAQ or GNA11 Mutations

IDEAYA and Pfizer Expand its CTC and Supply Agreement for Solid Tumors Harboring GNAQ or GNA11 Mutations

Shots:

  • The companies have expanded their clinical trial collaboration and supply agreement for IDE196 and crizotinib. The study will evaluate combination therapy in patients with solid tumors having GNAQ or GNA11 mutations (GNAQ/11), including MUM, skin melanoma, lung cancer, and colorectal cancer
  • The two global companies have established JDC and there will be joint decision making and data sharing of the clinical trial results between the parties. IDEAYA will sponsor the study and Pfizer will provide the crizotinib for the study, furthermore, IDEAYA is evaluating IDE196 as monothx. in an ongoing GNAQ/11 non-MUM basket trial
  • IDEAYA’s clinical development plan in MUM for IDE196 is based on combination therapies, including with binimetinib and crizotinib enabled via CTA and drug supply agreement with Pfizer. IDEAYA reported FPI for the IDE196 and binimetinib in Jun’2020 and is targeting FPI for the crizotinib clinical trial combination in late 2020 to early 2021

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Medical Dialogues

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post